Galapagos NV
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of …
Biotechnology
BE, Mechelen [HQ]
Similar Stocks · Benchmarked Analysis · Peer Group
Peer Group Analysis
Similar Stocks · Benchmarked Analysis · Peer GroupA quick analysis that compared Galapagos NV (GLPGF) to it's peer group, including competitors as well as it's industry. All monetary values in mil. except volume - volume is in thousands.
| Company | Price | Change | Volume, Avg. | Market Cap. | Revenue | Profit Net | Earnings | Free Cash Flow | Dividend Yield | P/E | EPS | Gross Margin % | Net Margin % | ROE % | ROA % | Quick Ratio % | Shares Outstanding | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biotechnology Average | - - | - - | - - | 36,972.82 | 12,670.30 | 584.01 | 282.25 | -1,045.34 | 0.00 | 21.8412 | 41.32 | -0.7623 | -19.2547 | -0.07 | -0.07 | 6.8104 | - - | ||
| Maximum | - - | - - | - - | 1,535,067.00 | 609,984.00 | 35,800.00 | 99,050.00 | 5,421.00 | 0.02 | 1,336.3467 | 2,849.43 | 3.0051 | 85.3485 | 0.38 | 8.35 | 61.5621 | - - | ||
| Minimum | - - | - - | - - | 0.00 | 0.00 | -10,603.00 | -56,335.00 | -50,658.00 | 0.00 | -164.8536 | -132.82 | -101.7758 | -1,444.7800 | -1.56 | -12.64 | 0.0844 | - - | ||
| Galapagos NV GLPGF | 24.66 | 0.00 0.00% | 0 vs. 0 | 1,625.00 | 62.00 | 90.00 | -124.00 | -133.00 | 1.3700 | 4.4516 | 0.0000 | 0.9592 | 1.4451 | 0.0312 | 0.0207 | 9.5496 | 65.00 | ||
| Barco NV BCNAF | 18.00 | 0.00 0.00% | 0 vs. 0 | 1,621.00 | - - | - - | - - | 615.00 | - - | - - | - - | - - | - - | - - | - - | - - | 90.00 | ||
More Due Diligence
Leverage our visualization and data tables to compare over 25 years of financial data for AAPL and its peers.